It was found that TSN can enhance cisplatin sensitization against non-small cell lung cancer cells through targeting Anxa4 in NSCLC cells, decreasing the combination of Anxa4 with ATP7A, and decreasing the extracellular efflux of platinum. Here, ATP7A is linked to non-small cell lung carcinoma.